31405-69-3

Basic information

• Product Name: 2’-hydroxy-5’-(methoxymethoxy)acetophenone
• Synonyms: 2’-hydroxy-5’-(methoxymethoxy)acetophenone
• CAS NO: 31405-69-3
• Molecular Weight: 196.203
• Mol File: 31405-69-3.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: 2’-hydroxy-5’-(methoxymethoxy)acetophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 2’-hydroxy-5’-(methoxymethoxy)acetophenone(31405-69-3)
• EPA Substance Registry System: 2’-hydroxy-5’-(methoxymethoxy)acetophenone(31405-69-3)

Safety Data

• Hazardous Substances Data: 31405-69-3(Hazardous Substances Data)

Upstream product

• 131341-58-7 2,5'-dihydroxy acetophenone 
• 107-30-2 chloromethyl methyl ether 
• 490-78-8 2,5-Dihydroxyacetophenone 

Downstream Products

• 6665-83-4 6-hydroxyflavone 
• 1234351-38-2 (Z)-5-hydroxy-2-benzylidene-benzofuran-3(2H)-one 

Relevant articles and documents

Design, synthesis and metabolic regulation effect of farnesoid X receptor (FXR) antagonistic benzoxepin-5-ones

A series of benzoxepin-5-ones were designed and synthesized by the cyclization of chalcones which were previously found as FXR antagonists. The cellular FXR antagonism of benzoxepines was investigated, among which the most potent compound 10l was able to reduce the plasma and hepatic triglyceride and plasma ALT levels in mice.

Design, synthesis, and evaluation of a water soluble C5-monoketone type curcumin analogue as a potent amyloid β aggregation inhibitor

A structure activity relationship study of curcumin analogues for the inhibition of amyloid β aggregation is described. Optimization of the o-phenol and olefin spacer resulted in the identification of the C5-monoketone type curcumin analogue AY1319, which

Benzoxy tropylium compound, preparation method of benzoxy tropylium compound, pharmaceutical composition and usages of pharmaceutical composition and benzoxy tropylium compound

The invention discloses a benzoxy tropylium compound shown as a formula I, a preparation method of the benzoxy tropylium compound, a composition containing the compound, and usage of the compound in the preparation of farnesoid ester X receptor antagonists, liver protective agents and medicaments for preventing hyperlipidemia and preventing type 2 diabetes mellitus. The formula I is shown in the description.